$WNLV
Winvest Group Ltd

2024 Q3 Form 10-Q Financial Statement

#000157587224000773 Filed on July 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q1 2023 Q1
Revenue $0.00 $64.84K $110.2K
YoY Change -100.0% -41.17%
Cost Of Revenue $36.92K $68.48K
YoY Change -46.09%
Gross Profit $27.92K $41.73K
YoY Change -33.09%
Gross Profit Margin 43.06% 37.86%
Selling, General & Admin $97.74K $696.5K
YoY Change -85.97% 364.28%
% of Gross Profit 350.07% 1669.15%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $153.1K $97.74K $696.5K
YoY Change 61.59% -85.97% 364.29%
Operating Profit -$153.1K -$69.82K -$654.8K
YoY Change 156.21% -89.34% 336.48%
Interest Expense $788.00 $1.211K $0.00
YoY Change -76.6%
% of Operating Profit
Other Income/Expense, Net -$12.00 $61.17K $0.00
YoY Change -99.64%
Pretax Income -$39.33K -$8.656K -$654.8K
YoY Change -37.71% -98.68% 336.47%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$39.33K -$8.656K -$654.8K
YoY Change -37.71% -98.68% 336.48%
Net Earnings / Revenue -13.35% -594.14%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.04
COMMON SHARES
Basic Shares Outstanding 85.16M 271.5M 17.47M
Diluted Shares Outstanding 271.5M 17.47M

Balance Sheet

Concept 2024 Q3 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $164.6K $93.67K
YoY Change 75.71%
Cash & Equivalents $289.0K $164.6K $93.67K
Short-Term Investments
Other Short-Term Assets $98.92K $9.930K
YoY Change 896.17%
Inventory
Prepaid Expenses $155.6K $98.92K $9.931K
Receivables $19.20K $9.200K $44.38K
Other Receivables $0.00 $0.00
Total Short-Term Assets $468.8K $272.7K $148.0K
YoY Change 276.84% 84.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $1.025M
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.930K
YoY Change
Other Assets $1.090K
YoY Change
Total Long-Term Assets $11.98K $11.02K $0.00
YoY Change 532.37%
TOTAL ASSETS
Total Short-Term Assets $468.8K $272.7K $148.0K
Total Long-Term Assets $11.98K $11.02K $0.00
Total Assets $480.8K $283.7K $148.0K
YoY Change 280.67% 91.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.378K $65.59K $36.34K
YoY Change -93.75% 80.51% 56.42%
Accrued Expenses $64.15K $49.79K $14.48K
YoY Change 302.49% 243.78%
Deferred Revenue
YoY Change
Short-Term Debt $620.9K $679.9K
YoY Change -8.68% 181.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.276M $986.3K $830.7K
YoY Change 29.24% 18.73% 214.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.276M $986.3K $830.7K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.276M $986.3K $830.7K
YoY Change 29.24% 18.73% 214.02%
SHAREHOLDERS EQUITY
Retained Earnings -$104.8M -$104.7M -$104.5M
YoY Change 0.14% 0.22%
Common Stock $285.2K $635.2K $17.53K
YoY Change 1456.04% 3524.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$795.6K -$702.5K -$682.7K
YoY Change
Total Liabilities & Shareholders Equity $480.8K $283.7K $148.0K
YoY Change 280.67% 91.73%

Cashflow Statement

Concept 2024 Q3 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$39.33K -$8.656K -$654.8K
YoY Change -37.71% -98.68% 336.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$112.7K -$61.53K
YoY Change 83.15% -53.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $61.65K
YoY Change
Cash From Investing Activities $61.65K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.6K $118.0K
YoY Change 44.48% -11.07%
NET CHANGE
Cash From Operating Activities -112.7K -$61.53K
Cash From Investing Activities 61.65K 0.000
Cash From Financing Activities 170.6K $118.0K
Net Change In Cash 119.5K $56.52K
YoY Change 111.46%
FREE CASH FLOW
Cash From Operating Activities -$112.7K -$61.53K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001558740
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NONE
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-56204
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
WINVEST GROUP LTD.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2052033
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
50 West Liberty Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 880
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Reno
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89501
CY2024Q1 dei City Area Code
CityAreaCode
(775)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
996-0288
CY2024Q1 dei Security12b Title
Security12bTitle
Winvest Group Ltd, Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
WNLV
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85159075
CY2024Q1 us-gaap Cash
Cash
164589
CY2023Q4 us-gaap Cash
Cash
45070
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9200
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4100
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
0
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
15710
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
98917
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-145422
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10861
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12590
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4524
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
15710
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
98917
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61230
CY2024Q1 us-gaap Assets Current
AssetsCurrent
272706
CY2023Q4 us-gaap Assets Current
AssetsCurrent
126110
CY2024Q1 us-gaap Investments
Investments
9925
CY2023Q4 us-gaap Investments
Investments
800
CY2024Q1 us-gaap Security Deposit
SecurityDeposit
1094
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
1094
CY2024Q1 us-gaap Assets
Assets
283725
CY2023Q4 us-gaap Assets
Assets
128004
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
65591
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76451
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54317
CY2024Q1 wnlv Project Advances Current
ProjectAdvancesCurrent
100000
CY2023Q4 wnlv Project Advances Current
ProjectAdvancesCurrent
100000
CY2024Q1 wnlv Project Advances Related Party
ProjectAdvancesRelatedParty
150000
CY2023Q4 wnlv Project Advances Related Party
ProjectAdvancesRelatedParty
150000
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
18670
CY2024Q1 wnlv Notes Payablerelated Parties Current
NotesPayablerelatedPartiesCurrent
620888
CY2023Q4 wnlv Notes Payablerelated Parties Current
NotesPayablerelatedPartiesCurrent
631157
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
986272
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1030595
CY2024Q1 us-gaap Liabilities
Liabilities
986272
CY2023Q4 us-gaap Liabilities
Liabilities
1030595
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
227838680
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
215689
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
227839
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
635159
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103175814
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103571797
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
283725
CY2024Q1 us-gaap Revenues
Revenues
64840
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
656328
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
40193
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
97743
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-69823
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-654791
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61230
CY2024Q1 us-gaap Assets Current
AssetsCurrent
272706
CY2023Q4 us-gaap Assets Current
AssetsCurrent
126110
CY2024Q1 us-gaap Security Deposit
SecurityDeposit
1094
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
1094
CY2024Q1 us-gaap Assets
Assets
283725
CY2023Q4 us-gaap Assets
Assets
128004
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
65591
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76451
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54317
CY2024Q1 wnlv Project Advances Current
ProjectAdvancesCurrent
100000
CY2023Q4 wnlv Project Advances Current
ProjectAdvancesCurrent
100000
CY2024Q1 wnlv Project Advances Related Party
ProjectAdvancesRelatedParty
150000
CY2023Q4 wnlv Project Advances Related Party
ProjectAdvancesRelatedParty
150000
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
18670
CY2024Q1 wnlv Notes Payablerelated Parties Current
NotesPayablerelatedPartiesCurrent
620888
CY2023Q4 wnlv Notes Payablerelated Parties Current
NotesPayablerelatedPartiesCurrent
631157
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
986272
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1030595
CY2024Q1 us-gaap Liabilities
Liabilities
986272
CY2023Q4 us-gaap Liabilities
Liabilities
1030595
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
215689
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
227839
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
635159
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18326
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103175814
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103571797
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104729209
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104720553
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-702547
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-902591
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
283725
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128004
CY2024Q1 us-gaap Revenues
Revenues
64840
CY2023Q1 us-gaap Revenues
Revenues
110209
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
36920
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
68479
CY2024Q1 us-gaap Gross Profit
GrossProfit
27920
CY2023Q1 us-gaap Gross Profit
GrossProfit
41730
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
215689
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18326075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18326
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103175814
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103571797
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104729209
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104720553
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-702547
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128004
CY2024Q1 us-gaap Revenues
Revenues
64840
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
97743
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
696521
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-69823
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-654791
CY2024Q1 us-gaap Interest Expense
InterestExpense
1211
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Other Income
OtherIncome
809
CY2023Q1 us-gaap Other Income
OtherIncome
0
CY2024Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
61569
CY2023Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8656
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-654791
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
271476008
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
271476008
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17466275
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17466275
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-485968
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
458040
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-654791
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-682719
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-902591
CY2024Q1 wnlv Stock Issued During Period Value Issued For Investment
StockIssuedDuringPeriodValueIssuedForInvestment
9200
CY2024Q1 wnlv Stock Issued During Period Value Issued On Private Placement
StockIssuedDuringPeriodValueIssuedOnPrivatePlacement
199500
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-8656
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-702547
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-8656
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
97743
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
656328
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
40193
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-69823
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-654791
CY2024Q1 us-gaap Interest Expense
InterestExpense
1211
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Other Income
OtherIncome
809
CY2024Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
61569
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8656
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-654791
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
271476008
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
271476008
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-702547
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-8656
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-654791
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
458040
CY2024Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
61569
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2024Q1 us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
5100
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15710
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16231
CY2024Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
37687
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-145422
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10861
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6555
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112686
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61525
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61645
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46538
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
199500
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
18670
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10269
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
80000
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
151510
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170561
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118048
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
119520
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
56523
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45070
CY2024Q1 us-gaap Interest Expense
InterestExpense
1211
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Other Income
OtherIncome
809
CY2023Q1 us-gaap Other Income
OtherIncome
0
CY2024Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
61569
CY2023Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
61167
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8656
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
271476008
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
271476008
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17466275
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17466275
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-654791
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-682719
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-902591
CY2024Q1 wnlv Stock Issued During Period Value Issued For Investment
StockIssuedDuringPeriodValueIssuedForInvestment
9200
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-654791
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
458040
CY2024Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
61569
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15710
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16231
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
37687
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-145422
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10861
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12590
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4524
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6555
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112686
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61525
CY2024Q1 us-gaap Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
61645
CY2023Q1 us-gaap Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61645
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46538
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
199500
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
18670
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10269
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
151510
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164589
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93670
CY2024Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
9200
CY2023Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
0
CY2024Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
61569
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15710
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16231
CY2024Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
37687
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-145422
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10861
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12590
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4524
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6555
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112686
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61525
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61645
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46538
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
199500
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
18670
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10269
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
151510
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118048
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
119520
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
56523
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164589
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93670
CY2024Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
9200
CY2023Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
0
CY2012Q1 wnlv Issuance Of Common Stock For Donated Service
IssuanceOfCommonStockForDonatedService
98984744
CY2021Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 250
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities at the date of the condensed consolidated financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</div></div>
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6555
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112686
CY2024Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46538
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
199500
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
18670
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10269
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
80000
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
151510
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118048
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
56523
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45070
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37148
CY2024Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
9200
CY2023Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
0
CY2012Q1 wnlv Issuance Of Common Stock For Donated Service
IssuanceOfCommonStockForDonatedService
98984744
CY2021Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 250
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities at the date of the condensed consolidated financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</div></div>
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37148
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164589
CY2024Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
9200
CY2023Q1 wnlv Purchase Of Investment With Common Shares
PurchaseOfInvestmentWithCommonShares
0
CY2012Q1 wnlv Issuance Of Common Stock For Donated Service
IssuanceOfCommonStockForDonatedService
98984744
CY2021Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 250
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities at the date of the condensed consolidated financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</div></div>
CY2024Q1 us-gaap Revenue Recognition Sales Of Services
RevenueRecognitionSalesOfServices
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Production – Cost of Revenue</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The cost of revenue is comprised of labor expenses calculated based on an hourly labor rate provided by consultants and employees to produce revenue, as well as portion of office expense which is allocated to each project. Additionally, the cost of revenue includes direct expenses related to the revenues provided, such as managing the client’s Amazon sales channel through the creation of promotional advertisements to increase sales, translation of content into different languages, coordination of projects with different work teams to maximize client benefits, production crew for celebrity endorsements and video shooting, and salaries and wages of employees involved in creating and delivering these services.</div></div>
CY2012Q1 wnlv Issuance Of Common Stock For Donated Service
IssuanceOfCommonStockForDonatedService
98984744
CY2021Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 250
CY2024Q1 wnlv Working Capital Deficit
WorkingCapitalDeficit
713566
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104729209
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities at the date of the condensed consolidated financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</div></div>
CY2024Q1 us-gaap Revenue Recognition Sales Of Services
RevenueRecognitionSalesOfServices
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Production – Cost of Revenue</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The cost of revenue is comprised of labor expenses calculated based on an hourly labor rate provided by consultants and employees to produce revenue, as well as portion of office expense which is allocated to each project. Additionally, the cost of revenue includes direct expenses related to the revenues provided, such as managing the client’s Amazon sales channel through the creation of promotional advertisements to increase sales, translation of content into different languages, coordination of projects with different work teams to maximize client benefits, production crew for celebrity endorsements and video shooting, and salaries and wages of employees involved in creating and delivering these services.</div></div>
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1810116
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
164589
CY2024Q1 us-gaap Revenue Recognition Sales Of Services
RevenueRecognitionSalesOfServices
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Production – Cost of Revenue</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The cost of revenue is comprised of labor expenses calculated based on an hourly labor rate provided by consultants and employees to produce revenue, as well as portion of office expense which is allocated to each project. Additionally, the cost of revenue includes direct expenses related to the revenues provided, such as managing the client’s Amazon sales channel through the creation of promotional advertisements to increase sales, translation of content into different languages, coordination of projects with different work teams to maximize client benefits, production crew for celebrity endorsements and video shooting, and salaries and wages of employees involved in creating and delivering these services.</div></div>
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1810116
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
164589
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
45070
CY2024Q1 us-gaap Revenue Recognition Sales Of Services
RevenueRecognitionSalesOfServices
<div style="font-size: 10pt; margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none;"><div style="color: rgb(0, 0, 0);text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">Production – Cost of Revenue</div></div></div><div style="margin: 0px 0px 0px 0in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;display:inline;">The cost of revenue is comprised of labor expenses calculated based on an hourly labor rate provided by consultants and employees to produce revenue, as well as portion of office expense which is allocated to each project. Additionally, the cost of revenue includes direct expenses related to the revenues provided, such as managing the client’s Amazon sales channel through the creation of promotional advertisements to increase sales, translation of content into different languages, coordination of projects with different work teams to maximize client benefits, production crew for celebrity endorsements and video shooting, and salaries and wages of employees involved in creating and delivering these services.</div></div>
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1810116
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
45070
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
0
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2023Q3 wnlv Conversion Of Stock Shares Additional Limit
ConversionOfStockSharesAdditionalLimit
9200000
CY2023Q3 wnlv Debt Conversion Converted Instrument Shares Agreement Grants
DebtConversionConvertedInstrumentSharesAgreementGrants
(i) the right to repurchase its Series A Preferred stock from the Company at a purchase price to be determined by IFA’s valuation at the time of repurchase; and (ii) anti-dilution protection in the event the Company issues any shares of its Common stock below $1.50 per share.
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
0
CY2023Q3 wnlv Conversion Of Stock Shares Additional Limit
ConversionOfStockSharesAdditionalLimit
9200000
CY2023Q3 wnlv Debt Conversion Converted Instrument Shares Agreement Grants
DebtConversionConvertedInstrumentSharesAgreementGrants
(i) the right to repurchase its Series A Preferred stock from the Company at a purchase price to be determined by IFA’s valuation at the time of repurchase; and (ii) anti-dilution protection in the event the Company issues any shares of its Common stock below $1.50 per share.
CY2024Q1 wnlv Proceeds From Sale Of Investment Shares
ProceedsFromSaleOfInvestmentShares
75332
CY2024Q1 wnlv Proceeds From Sale Of Investment
ProceedsFromSaleOfInvestment
61644
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
61569
CY2023Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
631157
CY2022Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
601649
CY2024Q1 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
4731
CY2024Q1 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
-15000
CY2023 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
0
CY2024Q1 wnlv Advances From Related Parties
AdvancesFromRelatedParties
620888
CY2023Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
631157
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
0
CY2023Q3 wnlv Conversion Of Stock Shares Additional Limit
ConversionOfStockSharesAdditionalLimit
9200000
CY2023Q3 wnlv Debt Conversion Converted Instrument Shares Agreement Grants
DebtConversionConvertedInstrumentSharesAgreementGrants
(i) the right to repurchase its Series A Preferred stock from the Company at a purchase price to be determined by IFA’s valuation at the time of repurchase; and (ii) anti-dilution protection in the event the Company issues any shares of its Common stock below $1.50 per share.
CY2024Q1 wnlv Proceeds From Sale Of Investment Shares
ProceedsFromSaleOfInvestmentShares
75332
CY2024Q1 wnlv Proceeds From Sale Of Investment
ProceedsFromSaleOfInvestment
61644
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
61569
CY2024Q1 us-gaap Investments
Investments
9925
CY2023Q4 us-gaap Investments
Investments
800
CY2024Q1 us-gaap Notes Payable
NotesPayable
0
CY2023Q4 us-gaap Notes Payable
NotesPayable
18670
CY2024Q1 wnlv Notes Payable Related Parties
NotesPayableRelatedParties
620888
CY2023Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
631157
CY2022Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
601649
CY2023Q3 wnlv Conversion Of Stock Shares Additional Limit
ConversionOfStockSharesAdditionalLimit
9200000
CY2023Q3 wnlv Debt Conversion Converted Instrument Shares Agreement Grants
DebtConversionConvertedInstrumentSharesAgreementGrants
(i) the right to repurchase its Series A Preferred stock from the Company at a purchase price to be determined by IFA’s valuation at the time of repurchase; and (ii) anti-dilution protection in the event the Company issues any shares of its Common stock below $1.50 per share.
CY2024Q1 wnlv Proceeds From Sale Of Investment Shares
ProceedsFromSaleOfInvestmentShares
75332
CY2024Q1 wnlv Proceeds From Sale Of Investment
ProceedsFromSaleOfInvestment
61644
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
61569
CY2024Q1 us-gaap Investments
Investments
9925
CY2023Q4 us-gaap Investments
Investments
800
CY2024Q1 wnlv Notes Payable Related Parties
NotesPayableRelatedParties
620888
CY2023Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
631157
CY2022Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
601649
CY2024Q1 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
4731
CY2024Q1 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
-15000
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2024Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1818
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1818
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 wnlv Proceeds From Sale Of Investment Shares
ProceedsFromSaleOfInvestmentShares
75332
CY2024Q1 wnlv Proceeds From Sale Of Investment
ProceedsFromSaleOfInvestment
61644
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
61569
CY2023Q4 us-gaap Investments
Investments
800
CY2024Q1 us-gaap Notes Payable
NotesPayable
0
CY2023Q4 us-gaap Notes Payable
NotesPayable
18670
CY2024Q1 wnlv Notes Payable Related Parties
NotesPayableRelatedParties
620888
CY2023Q4 wnlv Notes Payable Related Parties
NotesPayableRelatedParties
631157
CY2023Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
631157
CY2022Q4 wnlv Advances From Related Parties
AdvancesFromRelatedParties
601649
CY2024Q1 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
4731
CY2023 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
29508
CY2024Q1 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
-15000
CY2023 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
0
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2024Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1818
CY2024Q1 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
4731
CY2023 wnlv Additions Of Related Parties
AdditionsOfRelatedParties
29508
CY2024Q1 wnlv Repayments To Related Parties
RepaymentsToRelatedParties
-15000
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1818
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2024Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
98917
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
61230
CY2024Q1 wnlv Prepaid Expenses For Development Fees And Startup Fees
PrepaidExpensesForDevelopmentFeesAndStartupFees
15000
CY2024Q1 wnlv Prepaid Expenses For Mai Content
PrepaidExpensesForMAIContent
30750
CY2024Q1 wnlv Prepaid Expenses For Concept Artwork
PrepaidExpensesForConceptArtwork
20000
CY2024Q1 wnlv Prepaid Expenses For Other Retainer Fees For Legal Service
PrepaidExpensesForOtherRetainerFeesForLegalService
33167
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
54317
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 wnlv Project Advances
ProjectAdvances
250000
CY2023Q4 wnlv Project Advances
ProjectAdvances
250000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8656
CY2024Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1818
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-137506
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
137506
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
98917
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
61230
CY2024Q1 wnlv Prepaid Expenses For Development Fees And Startup Fees
PrepaidExpensesForDevelopmentFeesAndStartupFees
15000
CY2024Q1 wnlv Prepaid Expenses For Mai Content
PrepaidExpensesForMAIContent
30750
CY2024Q1 wnlv Prepaid Expenses For Concept Artwork
PrepaidExpensesForConceptArtwork
20000
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
54317
CY2024Q1 us-gaap Accrued Payroll Taxes Current And Noncurrent
AccruedPayrollTaxesCurrentAndNoncurrent
2066.64
CY2024Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
33371.5
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1818
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-654791
CY2024Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
98917
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
61230
CY2024Q1 wnlv Prepaid Expenses For Development Fees And Startup Fees
PrepaidExpensesForDevelopmentFeesAndStartupFees
15000
CY2024Q1 wnlv Prepaid Expenses For Mai Content
PrepaidExpensesForMAIContent
30750
CY2024Q1 wnlv Prepaid Expenses For Concept Artwork
PrepaidExpensesForConceptArtwork
20000
CY2024Q1 wnlv Prepaid Expenses For Other Retainer Fees For Legal Service
PrepaidExpensesForOtherRetainerFeesForLegalService
33167
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
54317
CY2024Q1 us-gaap Accrued Payroll Taxes Current And Noncurrent
AccruedPayrollTaxesCurrentAndNoncurrent
2066.64
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18326075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
us-gaap Share Based Compensation
ShareBasedCompensation
458040
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
855000
CY2021 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
855000
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
3420
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
227838680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2024Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Each share of preferred stock is convertible to 50 shares of common stock.
CY2024Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
98917
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
61230
CY2024Q1 wnlv Prepaid Expenses For Development Fees And Startup Fees
PrepaidExpensesForDevelopmentFeesAndStartupFees
15000
CY2024Q1 wnlv Prepaid Expenses For Concept Artwork
PrepaidExpensesForConceptArtwork
20000
CY2024Q1 wnlv Prepaid Expenses For Other Retainer Fees For Legal Service
PrepaidExpensesForOtherRetainerFeesForLegalService
33167
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
49793
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
54317
CY2024Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
33371.5
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4500000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
635159075
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18326075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
us-gaap Share Based Compensation
ShareBasedCompensation
458040
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
855000
CY2021 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
855000
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
3420
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
227838680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2024Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Each share of preferred stock is convertible to 50 shares of common stock.
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18326075
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18326075
us-gaap Share Based Compensation
ShareBasedCompensation
458040
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
855000
CY2021 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
855000
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
3420
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
227838680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2024Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Each share of preferred stock is convertible to 50 shares of common stock.
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
635159075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18326075
CY2021 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
855000
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
3420
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
300000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
215688680
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
215688680
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
227838680
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
227838680
CY2024Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Each share of preferred stock is convertible to 50 shares of common stock.

Files In Submission

Name View Source Status
0001575872-24-000773-index-headers.html Edgar Link pending
0001575872-24-000773-index.html Edgar Link pending
0001575872-24-000773.txt Edgar Link pending
0001575872-24-000773-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wg002_ex31-1.htm Edgar Link pending
wg002_ex31-2.htm Edgar Link pending
wg002_ex32-1.htm Edgar Link pending
wg002_ex32-2.htm Edgar Link pending
wnlv-20240331.htm Edgar Link pending
wnlv-20240331.xsd Edgar Link pending
wnlv-20240331_cal.xml Edgar Link unprocessable
wnlv-20240331_def.xml Edgar Link unprocessable
wnlv-20240331_htm.xml Edgar Link completed
wnlv-20240331_pre.xml Edgar Link unprocessable
wnlv-20240331_lab.xml Edgar Link unprocessable